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Background. There is limited information on the relative proportion of reactivation and reinfection at the
time of recurrence among human immunodeficiency virus (HIV)–infected and HIV-uninfected patients who are
successfully treated for tuberculosis infection in India.
Methods. HIV-infected and HIV-uninfected patients with sputum culture–positive pulmonary tuberculosis
were treated with short-course regimens and followed up for 36 months at the Tuberculosis Research Centre,
South India. Bacteriologic recurrences were documented, and typing of strains was performed using 3 different
genotypic techniques: restriction fragment length polymorphism (RFLP) by IS6110, spoligotyping, and mycobac-
terial interspersed repeat unit (MIRU)–variable number tandem repeat (VNTR). DNA fingerprints of paired
Mycobacterium tuberculosis isolates (baseline and recurrence) were compared.
Results. Among 44 HIV-infected and 30 HIV-uninfected patients with recurrent tuberculosis during the period
July 1999 to October 2005, 25 and 23 paired isolates, respectively, were typed using all 3 methods. Recurrence
was due to exogenous reinfection in 88% of HIV-infected and 9% of HIV-uninfected patients ( ). AmongP ! .05
recurrent isolates, the HIV-infected patients showed more clustering, as well as a higher proportion of drug
resistance, including multidrug resistance.
Conclusions. In India, a tuberculosis-endemic country, most recurrences after successful treatment of tu-
berculosis are due to exogenous reinfection in HIV-infected persons and endogenous reactivation in HIV-un-
infected persons. Strategies for prevention and treatment of tuberculosis infection must take these findings into
consideration.
The human immunodeficiency virus (HIV) pandemic
has increased the burden of tuberculosis, especially in
populations where HIV infection is common and where
the prevalence of tuberculosis was already high [1, 2].
The worldwide estimate is that nearly 2 billion people
are infected with Mycobacterium tuberculosis, 33 million
are infected with HIV, and 12 million are dually infect-
ed [3]. According to the World Health Organization
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(WHO) 2008 global report on tuberculosis, 700,000 of
the 9.2 million new tuberculosis cases reported in 2006
occurred among HIV-infected people [4]. HIV has an
effect on the incidence, prevalence, clinical presenta-
tion, diagnostic yield, and treatment options for pa-
tients with tuberculosis. The developing world has the
highest burden of both diseases [5].
India has 20% of the global burden of tuberculosis
infections, with 1.8 million new cases each year, as well
as a large pool (∼2.5 million) of HIV-infected individ-
uals [4, 5]. This sets the stage for a deadly synergy
between the 2 infections. The risk of developing tu-
berculosis disease for HIV-infected patients in India is
estimated to be 7 cases per 100 person-years at risk,
compared with the 10% lifetime risk of an immuno-
competent host [6]. Even though the initial bacterio-
logic response to antituberculosis therapy is similar in
both HIV-infected and HIV-uninfected patients, re-
currences of tuberculosis infection are more frequent
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among coinfected patients, especially in countries with high
rates of tuberculosis infection [7]. Recurrences of tuberculosis
could be due to either exogenous reinfection or endogenous
reactivation, and the 2 can be differentiated by molecular typ-
ing. For decades, the issue of the role played by exogenous
reinfection versus endogenous reactivation has been debated
[8, 9]. We have earlier shown that endogenous reactivation
predominates in patients with tuberculosis not infected with
HIV [10]. However, there are no data with regard to HIV-
coinfected patients with tuberculosis from India and limited
data from other parts of the world [11, 12]. It is likely that the
presence of HIV in communities could modify the pattern of
tuberculosis transmission.
There are several genotyping tools, including restriction frag-
ment length polymorphism (RFLP) typing, spoligotyping, and
mycobacterial interspersed repeat unit (MIRU)–variable num-
ber tandem repeat (VNTR) typing that are used to differentiate
tuberculosis strains. Each of these techniques has its own ad-
vantages and disadvantages. It is preferable to use more than
1 method to accurately assess the source of the tuberculosis
strain that is infecting patients. In the present study, we com-
pared the relative proportions of reinfection or reactivation
among recurrence isolates of M. tuberculosis from HIV-infected
and HIV-uninfected patients enrolled in clinical trials and fol-
lowed up at the Tuberculosis Research Centre (TRC), Chennai,
India. All patients were well characterized at baseline, treated
under similar conditions with short-course regimens, and fol-
lowed up regularly to document treatment outcomes. Our aims
were to study the role of HIV infection in tuberculosis trans-
mission in a tuberculosis-endemic setting and also the relative
performance of the 3 genotypic methods in classifying strains.
METHODS
Study population and setting. The study was conducted at
the TRC’s clinics in Chennai and Madurai, South India, from
July 1999 to October 2005. The Institutional Ethics committee
had approved the clinical trials, and all patients provided writ-
ten informed consent. Patients were evaluated for the presence
of HIV and tuberculosis, as well as their suitability for clinical
trials. A standardized questionnaire was administered by a phy-
sician, clinical examination was performed, and a chest radi-
ograph was taken. HIV infection was diagnosed on the basis
of 3 tests: samples found positive using the TRIDOT rapid test
(J Mitra) were next tested with CombAids (Span Diagnostics,
India), followed by an enzyme-linked immunosorbent assay
(Lab Systems, India). Tuberculosis was suspected on the basis
of clinical and radiographic features, and diagnosis was con-
firmed by mycobacterial culture.
Patients were recruited for clinical trials if they fulfilled the
clinical and laboratory eligibility criteria. HIV-infected patients
included in this analysis were from a pilot study of 6-month
short-course treatment and a randomized clinical trial com-
paring 6 and 9 months of treatment (NCT 00376012). Patients
received a standard short-course antituberculosis regimen con-
sisting of ethambutol (1200 mg), isoniazid (600 mg), rifampin
(450 or 600 mg for patients weighing !60 or 160 kg, respec-
tively), and pyrazinamide (1500 mg) thrice-weekly for the ini-
tial 2 months (intensive phase, 2EHRZ3), followed by rifampin
and isoniazid thrice-weekly for the next 4 or 7 months (con-
tinuation phase, 4/7RH3) [13]. All doses in the intensive phase
and 1 dose per week in the continuation phase were directly
observed. Surprise pill counts at home, urine tested for ace-
tylisoniazid, and return of empty pill covers were done to check
adherence. Patients included in the efficacy analysis had ad-
herence 180%, and most of the bacteriologic recurrences came
from this group. Patients did not have access to antiretroviral
treatment during the course of this study.
Of the 25 HIV-negative patients with recurrent disease in
the study, 12 had been treated with the same short-course
regimen (2EHRZ3/4RH3) at the same dosages, whereas 11 were
treated with regimens containing ofloxacin (3 months of daily
isoniazid [300 mg], rifampin [450 or 600 mg, depending on
the patient’s weight], pyrazinamide [1500 mg], and ofloxacin
[400 mg], followed by 1 or 2 months of thrice-weekly isoniazid
and rifampin), as they were enrolled in a trial assessing the
efficacy of fluoroquinolones [14]. Patients were reviewed clin-
ically and with sputum examination every month up to 24
months and every 3 months thereafter, until 36 months from
treatment initiation.
Bacteriologic methods. Three sputum samples were col-
lected at baseline and every month during treatment, and 2
sputum samples were collected every month during the follow-
up period. Sputum smears were examined for acid-fast bacillus
(AFB) by fluorescence microscopy before being processed by
the modified Petroff method and cultured on Lowenstein-Jen-
sen medium for 8 weeks. Species identification was performed
using standard biochemical tests and drug susceptibility tests
by standard methods at the TRC, a WHO supranational ref-
erence laboratory for mycobacteria [15].
Molecular typing methods. Genomic DNA was extracted
from M. tuberculosis cultures by standard cetyltrimethyl am-
monium bromide (CTAB)–NaCl extraction method [16].
IS6110 DNA fingerprinting was done according to interna-
tionally accepted guidelines [17]. Spoligotyping was performed
using standard methods [18]. In brief, the spacers between the
direct repeats in the target region were amplified by using a
primer set, primer Dra 5′-CC AAG AGG GGA CGG AAA C-
3′ and biotinylated primer Drb 5′-GGT TTT GGG TCT GAC
GAC-3′. The polymerase chain reaction (PCR) products were
then hybridized to a Biodyne C membrane (Isogen Bioscience).
This membrane contains immobilized synthetic oligomeric
spacer sequences derived from the direct-repeat region of M.
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Figure 1. Profile of patients enrolled in human immunodeficiency virus
(HIV) clinical trials and followed up, for whom baseline Mycobacterium
tuberculosis isolates were available.
tuberculosis H37Rv and Mycobacterium bovis BCG. Hybridized
DNA was detected using an enhanced chemiluminescence kit
(Amersham International), with exposure to X-ray film pro-
ducing a pattern or profile reminiscent of a bar code.
MIRU-VNTR genotyping was performed by using multiplex
PCR, X-Rhomadine-labeled MapMarker 1000, standard size
(BioVentures), and ABI 3100 and ABI 3730-XL sequencers (Ap-
plied Biosystems). Sizing of the PCR fragments and assignment
of the various VNTR alleles were performed by using custom-
ized GeneScan and Genotyper (version 2.0) or Genemapper
software packages (PE Applied Biosystems). All results were
entered into Microsoft Excel (version 2003) in a digital format
[19]. Patterns obtained by the different methods were analyzed
using Bionumerics software (version 5.0; Applied Maths). Sep-
arate databases were created for both HIV-infected and HIV-
uninfected patients with tuberculosis, and RFLP images were
scanned and loaded as the primary genotyping method. Spo-
ligotyping and MIRU data were loaded into these databases as
a character type in numerical code. These data were linked to
the respective sample number so that for a single sample all 3
typing data were available for comparison. If the fingerprint
patterns were identical (number and position of bands, spots,
and peaks) by all 3 methods or differed by 1 band, spot, or
peak, the recurrence was classified as reactivation, whereas if
the patterns differed by 2 or more bands, spots, or peaks by
any of the methods, the recurrence was classified as reinfection.
Clustering analysis was done by similarity matrix using Jaccard
coefficient, and dendrograms were drawn by unweighted pair
group method using arithmetic averages (UPGMA) using Bio-
numerics software (Applied Maths).
Statistical Analysis. We used x2 test with Yates continuity
correction or Fisher exact test as appropriate to compare pro-
portions. A P value of !.05 was regarded as significant.
RESULTS
In total, 387 HIV-infected patients with culture-confirmed pul-
monary tuberculosis were treated, and 306 (79%) were declared
cured (all sputum specimen results were negative during the
last 2 months of treatment). The mean age of the patients was
34 years; mean weight was 44 kg, 77% were men, and the
median CD4 count was 160 cells/mL. Of the 44 (14.4%) doc-
umented recurrences, results from all 3 genotyping methods
for both time points were available for 25 patients. We com-
pared the demographic characteristics of patients whose isolates
were not typed ( ) with those patients whose isolates werenp 14
typed ( ). Patients were similar in terms of age (mean,np 15
34 and 33 years, respectively), sex distribution, weight (mean,
42.6 and 44 kg, respectively), socioeconomic status, and median
viral load (257,844 and 209,227 copies/mL, respectively). Mean
CD4 cell count was 220 cells/mL in patients whose isolates were
typed versus 165 cells/mL in those whose isolates were not typed.
Figure 1 is a schematic representation of patients enrolled in
HIV clinical studies and followed up, for whom baseline M.
tuberculosis isolates were available.
During the same period, a large number of HIV-uninfected
patients with pulmonary tuberculosis were treated at the TRC.
Genotypic results of paired isolates using all 3 methods were
available for 23 patients; their mean age was 37 years, mean
weight was 42.1 kg, and 79% were men. Tables 1 and 2 show
the genotyping results and drug susceptibility pattern of all
patients using the 3 different methods. We found that in 22
(88%) of 25 HIV-infected patients, the recurrence was due to
a new strain of tuberculosis, whereas in 21 (91%) of 23 HIV-
uninfected patients recurrence was due to the same strain
( ). To rule out cross-contamination as a reason for ap-P ! .05
parent exogenous reinfection, we examined serial isolates from
several patients at and after recurrence and looked for consis-
tency of results. The number of serial isolates obtained from
patients ranged from 2 to 8, and all of them were concordant
with their respective primary isolates. Among recurrences, 10
HIV-infected and 5 HIV-uninfected patients had isolates resis-
tant to 1 or more drugs; 6 HIV-infected and 2 HIV-uninfected
patients had isolates that were multidrug resistant. Figure 2
shows the timing of recurrence, by type and HIV status. Al-
though most reactivation of disease tended to occur within 12
months of completion of treatment, at least half of all reinfec-
tions occurred after 12 months.
IS6110 RFLP data revealed that both groups of patients had
a high proportion (45% and 47%, respectively) of IS6110 single
copy M. tuberculosis isolates. There was no significant difference
in the distribution of IS6110 types between the 2 groups. Eleven
percent of HIV-infected and 20% HIV-uninfected patients with
tuberculosis were infected with 2–5-copy strains, although no-
Table 1. Genotyping of Paired Tuberculosis Isolates from Human Immunodeficiency Virus (HIV)–Positive Patients
Patient Sex Age RFLP Month
Exogenous or
Endogenous Spoligotyping Spoligo ST MIRU SHRE
1 M 27 2J 0 Exo 474377777413771 EAI5 340 8 2 3 4 3 5 2 4 6 1 4 1
3 10 6
SSSS
6AB 7 477777777413071 EAI3_IND 11 5 2 4 4 3 3 2 4 6 1 4 1
3 6 6
SSSS
2 M 33 1B 0 Exo 777777777003731 EAI5 5 2 3 2 3 4 2 2 6 0 0 0
5 12 4
SSSS
3F 20 477777777413071 EAI3_IND 11 5 2 4 4 3 4 2 4 6 1 4 1
3 6 2
SSSS
3 M 43 1A 0 Exo 477777777413071 EAI3_IND 11 2 4 5 4 4 3 3 2 6 1 2 5
4 0 1
SSSS
1A 8 477777777413771 EAI3 126 2 4 5 4 4 3 6 0 0 1 2 5
4 0 1
SSSS
4 M 30 11R 0 Exo 577777774000771 ORPHAN 2 5 3 5 3 3 2 3 3 4 3 3
7 3 5
SSSS
1A 41 474377777413771 EAI5 340 0 2 3 4 3 5 2 3 6 1 4 1
3 7 5
SSSS
5 M 27 11S 0 Exo 000000000003771 Beijing 1 2 6 3 3 1 4 3 3 4 4 3 4
7 4 9
SSSS
11AO 18 777777777700771 U 124 2 5 3 5 3 3 2 3 3 4 3 3
7 3 5
SSSS
6 M 63 1A 0 Exo 401777777413071 EAI3_IND 473 5 2 4 4 3 4 2 4 6 1 10
1 3 6 4
SSSS
3A 20 473777777413771 EAI5 340 5 2 2 4 3 5 2 4 6 1 4 1
3 6 2
SSSS
7 F 25 1A 0 Exo 477777777413071 EAI3_IND 11 5 2 4 4 3 4 2 4 6 1 4 1
3 6 2
SRSS
1A 14 477777777413071 EAI3_IND 11 5 2 4 4 3 5 2 4 6 1 2 1
3 6 5
SSSS
8 M 30 1A 0 Exo 477777777413071 EAI3_IND 11 5 2 4 4 3 5 2 4 6 1 2 1
3 7 6
SSSS
3AI 35 777777777413700 EAI5 138 5 2 0 6 2 3 2 2 5 2 5 1
7 7 5
SSSS
9 F 30 1A 0 Endo 477777777413071 EAI3_IND 11 7 1 5 4 3 4 2 4 6 1 4 1
3 7 7
SSSS
1A 12 477777777413071 EAI3_IND 11 7 2 5 4 3 4 2 4 6 1 4 1
3 7 7
SSSS
10 F 27 3G 0 Exo 477777777413071 EAI3_IND 11 5 2 4 4 3 4 2 4 6 1 4 1
2 6 4
SSSS
1A 24 477777777413071 EAI3_IND 11 2 1 2 5 1 3 1 2 3 4 3 1
2 3 8
SSSS
11 M 37 14J 0 Exo 703777740003771 CAS1_DELHI 26 2 7 3 6 4 5 4 2 4 2 2 1
2 4 8
SSSS
3X 9 403777760003771 ORPHAN 8 2 3 4 3 5 2 3 6 1 4 1
3 7 5
SSSS
12 M 25 1A 0 Endo 477777777413771 EAI 5 126 5 2 2 4 3 5 2 4 6 1 4 1
3 6 3
SSSS
1A 7 477777777413771 EAI 5 126 5 2 2 4 3 5 2 4 6 1 4 1
3 6 2
SSSS
13 M 40 6AB 0 Exo 475773777413071 ORPHAN 4 2 4 4 3 4 2 3 6 1 4 1
2 7 5
SSSS
6AB 17 477777777413071 EAI3_IND 11 4 2 4 4 3 4 2 3 6 1 4 1
2 7 5
SSSS
14 M 29 1E 0 Exo 777777737760731 ORPHAN 2 1 2 5 1 3 3 4 3 4 3 3
2 4 0
SSSS
15K 37 000000000003771 Beijing 1 2 0 0 3 3 5 4 4 4 4 5 2
6 6 8
RRRS
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Table 1. (Continued.)
Patient Sex Age RFLP Month
Exogenous or
Endogenous Spoligotyping Spoligo ST MIRU SHRE
15 M 40 12AF 0 Exo 703777740003011 ORPHAN 2 7 3 6 5 5 4 2 4 2 2 2
2 3 8
SSSS
1A 8 777777777700771 U 124 0 2 4 4 3 4 2 4 4 1 3 1
3 4 6
SRSS
16 M 32 1A 0 Exo 477777777413071 EAI3_IND 11 2 4 5 4 4 3 4 2 4 1 2 4
4 7 1
SSSS
1A 15 477777777413771 EAI 5 126 2 4 4 4 4 3 4 3 6 1 2 6
4 6 1
SRRR
17 M 45 9W 0 Exo 777777663560771 T1 573 3 4 2 2 4 3 3 2 1 1 5 2
2 0 2
RSSS
10S 20 777777607760771 LAM9 42 5 4 2 1 4 2 3 3 1 1 5 3
2 4 2
SRRR
18 M 36 1A 0 Exo 401367777413071 ORPHAN 2 2 4 4 3 4 2 4 6 1 4 1
3 6 4
SSRS
1A 17 401777777413071 EAI3_IND 473 5 2 4 4 3 4 2 4 6 1 4 1
3 6 4
SSRS
19 M 33 6T 0 Exo 477777777413071 EAI3_IND 11 2 4 5 4 4 3 6 0 0 1 2 4
4 0 1
SSSS
6T 20 477777777413071 EAI3_IND 11 2 4 5 4 4 3 0 2 0 1 2 4
4 0 1
SRSS
20 M 32 9X 0 Exo 777777774000771 ORPHAN 2 5 3 5 3 3 2 3 3 4 3 3
3 3 5
SSSS
1A 9 777777777413771 EAI5 236 2 2 3 3 3 3 2 3 3 1 3 1
5 6 8
SSRS
21 M 27 1A 0 Exo 477777777413031 EAI5 355 2 4 2 4 4 3 3 3 6 1 2 4
4 4 1
SSSS
10S 7 777777607760771 LAM9 42 5 4 2 1 4 2 3 3 1 1 5 3
2 0 2
SRRR
22 M 27 1A 0 Exo 477777777413031 EAI5 355 2 4 2 4 4 3 6 3 6 1 2 4
4 0 1
SRSR
10S 17 777777607760771 LAM9 42 5 4 2 1 4 2 3 2 1 1 5 3
2 0 2
SRRR
23 F 21 1A 0 Endo 477777777413071 EAI3_IND 11 5 2 3 4 3 4 2 4 6 1 4 1
3 6 6
SSSS
1A 24 477777777413071 EAI3_IND 11 5 2 4 4 3 4 2 4 6 1 4 1
3 6 6
SSSS
24 M 27 3V 0 Exo 477777777413001 ORPHAN 2 4 5 4 4 3 6 2 0 1 2 4
5 0 1
SSSS
7X 16 477777777413071 EAI3_IND 11 2 4 5 4 4 3 3 3 1 1 2 4
4 0 1
SRRS
25 F 38 14G 0 Exo 703777740000171 CAS1_DELHI 1789 2 7 3 6 5 5 2 2 4 2 3 2
2 5 6
SSSS
10V 24 777777774020771 H1 47 2 5 4 5 3 3 2 3 3 4 3 3
3 3 7
SSSS
NOTE. MIRU, mycobacterial interspersed repeat unit; RFLP, restriction fragment length polymorphism; SHRE, streptomycin, isoniazid, rifampin,andethambutol;
ST, spoligotype.
copy strains were rare (Figure 3). Figure 4 shows the spoli-
gotyping data of isolates from HIV-infected and HIV-unin-
fected patients with tuberculosis at baseline and recurrence. M.
tuberculosis isolates of EAI3 clade were more common among
HIV-infected patients (49%) than HIV-uninfected patients with
tuberculosis (38%) ( ), whereas the EAI5 clade was moreP ! .05
common among HIV-uninfected patients (26% vs 18%; P !
). The Beijing genotype was present in 4% of HIV-infected.05
patients and none of the HIV-uninfected patients.
There were 6 MIRU clusters of 2 isolates each, which were
differentiated by spoligotyping or IS6110 RFLP (data not
shown). Table 3 shows 4 spoligotyping and IS6110 clusters
ranging from 2 to 10 isolates, which were differentiated by
MIRU. Tables 4 and 5 show the clustering of strains among
Table 2. Genotyping of Paired Tuberculosis Isolates from HIV-Negative Patients with Tuberculosis
Patient Sex Age RFLP Month
Exogenous or
Endogenous Spoligotyping Spoligo ST MIRU SHRE
1 M 45 1A 0 Exo 477774377413771 ORPHAN 2 4 5 4 4 3 7 3 2 1 2 4
4 7 1
SRSS
1A 24 477743774413071 ORPHAN 2 4 5 4 4 3 7 3 6 1 2 4
4 7 1
RRSR
2 F 23 1A 0 Endo 777777777413731 EAI1_SOM 48 2 2 5 3 4 3 9 6 9 2 2 5
5 4 1
RRSS
1A 24 777777777413731 EAI1_SOM 48 2 2 5 3 4 3 9 6 9 2 2 5
5 4 1
RRRS
3 M 65 2G 0 Exo 477777777413771 EAI5 126 2 4 5 2 4 3 6 3 6 1 2 5
4 4 1
SSSS
4E 24 700176777760671 ORPHAN 4 3 2 4 4 3 3 3 3 4 5 3
3 8 1
SRSS
4 M 51 2H 0 Endo 777777777760600 T1 243 4 4 2 4 4 3 2 3 3 4 5 3
3 8 3
SSSS
2H 18 777776777760600 ORPHAN 4 4 2 4 4 3 2 3 3 4 5 3
3 8 3
SSSS
5 M 56 1A 0 Endo 467777777413071 ORPHAN 2 5 5 0 4 3 6 3 6 1 2 5
4 4 1
SSSS
1A 18 477777777413071 EAI3_IND 11 2 5 5 0 4 3 6 3 6 1 2 5
4 4 1
SSSS
6 M 51 1A 0 Endo 467777757413071 ORPHAN 2 4 7 4 4 3 6 3 6 1 2 4
4 4 1
SSSS
1A 18 467777757413071 ORPHAN 2 4 7 4 4 3 6 3 6 1 2 4
4 4 1
SSSS
7 M 50 1A 0 Endo 476377777413771 ORPHAN 2 3 5 3 4 3 7 3 6 1 2 5
4 5 1
SSSS
1A 12 474377777413771 ORPHAN 2 3 5 3 4 3 7 3 6 1 2 5
4 5 1
SSSS
8 M 40 2C 0 Endo 477777777413071 EAI3_IND 11 2 4 2 4 4 3 7 3 6 1 2 4
4 3 1
SSSS
2C 12 477777777413071 EAI3_IND 11 2 4 2 4 4 3 7 3 6 1 2 4
4 3 1
SSSS
9 M 53 1A 0 Endo 477777777413031 EAI5 355 2 4 5 4 4 3 5 3 4 1 2 4
4 6 1
SSSS
1A 12 477777777413031 EAI5 355 2 4 5 4 4 3 5 3 4 1 2 4
4 6 1
SSSS
10 F 32 4B 0 Endo 477777777413071 EAI3_IND 11 2 4 5 4 4 3 6 3 5 1 2 4
4 6 1
RRSS
4B 18 477777777413071 EAI3_IND 11 2 4 5 4 4 3 6 3 5 1 2 4
4 6 1
RRSS
11 M 60 2D 0 Endo 474377777413671 ORPHAN 2 4 5 3 4 3 10 3 6 1 2
5 4 6 1
SSSS
2D 12 474377777413771 EAI5 340 2 4 5 3 4 3 10 3 6 1 2
5 4 6 1
SSSS
12 M 24 14K 0 Endo 703777740003771 CAS1_DELHI 26 4 2 2 4 6 4 4 2 4 4 7 4
6 7 4
SRSS
14K 12 703777740003771 CAS1_DELHI 26 4 2 2 4 6 4 4 2 4 4 7 4
6 7 4
SRSS
13 M 30 1A 0 Endo 477777777413031 EAI 5 355 8 2 4 4 3 4 2 4 6 1 9 1
3 6 6
SSSS
1A 7 477777777413071 EAI3_IND 11 8 2 4 4 3 4 2 4 6 1 9 1
3 6 6
SSSS
14 F 22 10F 0 Endo 700777740003771 CAS1_DELHI 26 2 5 3 6 3 5 4 2 4 2 3 3
2 4 8
SSSS
10F 8 700377740003771 CAS1_DELHI 26 2 5 3 6 3 5 4 2 4 2 3 4
2 4 8
SSSS
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Table 2. (Continued.)
Patient Sex Age RFLP Month
Exogenous or
Endogenous Spoligotyping Spoligo ST MIRU SHRE
15 M 20 13AC 0 Endo 777777777760771 T1 53 2 5 1 3 1 3 2 4 3 2 4 2
3 2 5
SSSS
13AC 7 777777777760771 T1 53 2 5 1 3 1 3 2 4 3 2 4 2
3 2 5
SSSS
16 M 55 1A 0 Endo 477777777413031 EAI 5 355 5 2 4 6 3 4 2 4 6 1 4 1
3 6 6
SSSS
1A 15 477777777413031 EAI 5 355 5 2 4 6 3 4 2 4 6 1 4 1
3 6 6
RRSS
17 M 45 1A 0 Endo 474000377413031 ORPHAN 5 2 4 4 3 4 2 4 5 1 4 1
3 6 7
SSSS
1A 10 474000377413031 ORPHAN 5 2 4 4 3 4 2 4 5 1 4 1
3 6 7
SSSS
18 F 32 1A 0 Endo 477777777413031 EAI 5 355 5 2 4 4 3 4 2 4 6 1 2 1
3 6 6
SSSS
1A 9 477777777413031 EAI 5 355 5 2 4 4 3 4 2 4 6 1 2 1
3 6 6
SSSS
19 M 48 12AI 0 Endo 777777763560371 ORPHAN 2 5 2 4 3 2 3 5 2 1 2 2
2 3 6
SRSS
12AI 7 777777663560371 ORPHAN 2 5 2 4 3 2 3 5 2 1 2 2
2 3 6
SRRS
20 M 18 1A 0 Endo 477777777403071 ORPHAN 5 2 4 4 3 4 2 4 6 1 4 1
3 6 6
SSSS
1A 8 477777777413071 EAI3_IND 11 5 2 4 4 3 4 2 4 6 1 4 1
3 6 6
SSSS
21 M 44 11Y 8 Endo 777777770020771 H3 742 2 5 2 2 3 3 0 4 3 2 3 2
3 3 6
SSSS
11Y 0 777777770020771 H3 742 2 5 4 2 3 3 0 4 3 2 3 2
3 3 6
SSSS
22 M 52 10AK 0 Endo 777777777700771 U 124 2 5 3 5 3 3 2 3 3 4 3 3
5 3 5
SSSS
10AK 9 777777777700771 U 124 2 5 3 5 3 3 2 3 3 4 3 3
5 3 5
SSSS
23 M 23 10AK 0 Endo 777777777700771 U 124 2 5 3 5 3 3 2 3 3 4 3 3
1 3 3
SSSS
10AK 8 777777777700771 U 124 2 5 3 5 3 3 2 3 3 4 3 3
6 3 3
SSSS
NOTE. MIRU, mycobacterial interspersed repeat unit; RFLP, restriction fragment length polymorphism; SHRE, streptomycin, isoniazid, rifampin, and etham-
butol; ST, spoligotype.
recurrence isolates among HIV-uninfected and HIV-infected
patients, respectively. Recurrences among HIV-infected pa-
tients tended to have more clustering. The dendrograms in
Figure 5A and 5B show the clustering pattern of HIV-infect-
ed and HIV-uninfected patients with tuberculosis by usable
DNA recovered. The distance between the isolates represents
the similarity index of individual isolates calculated by Jaccard
coefficient.
DISCUSSION
The fact that persons previously infected with M. tuberculosis
could be exogenously reinfected has been well documented [20–
23]. However, this was thought to occur rarely because of the
immunity conferred by primary infection. The pandemic of
HIV has modified the epidemiological profile, pathogenesis,
and clinical manifestations of tuberculosis [24, 25]. Distin-
guishing between recurrence due to endogenous reactivation
or to exogenous reinfection is essential to accurately determine
the efficacy of tuberculosis treatment regimens. The contri-
bution of recurrence to the epidemiological profile and path-
ogenesis of tuberculosis also has important implications for
vaccine design, chemoprophylaxis, and design of national tu-
berculosis control programs. This distinction is particularly im-
portant in settings with high tuberculosis prevalence. In the
absence of clinical or epidemiological pointers to the origin of
a tuberculosis episode being due to recent or reactivated in-
fection, molecular epidemiological analysis has played a sub-
stantial role in clarifying the issue. In this study, we have com-
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Figure 2. Time of endogenous reactivation and exogenous reinfection
among recurrence isolates. Tuberculosis recurrence by time period and
human immunodeficiency virus (HIV) status.
Figure 3. IS6110 restriction fragment length polymorphism (RFLP) of tuberculosis isolates from human immunodeficiency virus (HIV)–infected and
HIV-uninfected patients, at baseline and recurrence.
pared pretreatment isolates of M. tuberculosis with isolates at
the time of recurrence among HIV-infected and HIV-unin-
fected patients with tuberculosis treated with short-course an-
tituberculosis regimens in South India. Our objectives were to
examine the role played by HIV infection in determining the
type of tuberculosis recurrence (ie, relative frequency of en-
dogenous reactivation versus that of exogenous reinfection) in
a high tuberculosis prevalence setting, as well as to study the
performance of 3 molecular typing methods (IS6110 RFLP,
spoligotyping, and analysis of MIRU-VNTR).
In previous studies from TRC using a combination of DR-
and IS6110-RFLP typing, a high rate of endogenous reactivation
was reported among HIV-uninfected patients with tuberculosis
[26]. In contrast, in this study conducted in the same setting,
we have clearly shown that the majority (88%) of recurrences
among HIV-infected patients with tuberculosis are due to re-
infection with a new strain of M. tuberculosis. Among HIV-
uninfected patients with tuberculosis during the same period,
∼9% of recurrences were due to exogenous reinfection, where-
as the majority (190%) were due to endogenous reactivation.
These results show that reinfection is much more common in
patients with tuberculosis who are coinfected with HIV, par-
ticularly in the presence of immunosuppression. A study among
South African mine workers also showed predominance of re-
infection among HIV-infected (62%) and more of endogenous
reactivation among HIV-uninfected patients with tuberculosis
(94%) [27], which is similar to our findings. There has been
wide variability in studies involving patients with negative or
unknown HIV status, with reinfection accounting for 18%–
80% of recurrences in countries with low incidence of tuber-
culosis and 6%–80% in countries with high incidence of tu-
berculosis [7, 28, 29].
The dendrogram shows 5 major clusters among tuberculosis
isolates (baseline and recurrence) from HIV-infected patients
and 2 clusters among HIV-uninfected patients, suggesting that
the former are more heterogeneous in nature, probably because
exogenous reinfection was more common. We considered the
possibility that different fingerprints at various time points ob-
served among HIV-infected patients with tuberculosis in this
study could have arisen from either true new infection or mis-
classification. Over time, mutations or transpositions can alter
the fingerprint pattern of a strain, resulting in overestimation
of reinfection. We addressed this potential error by examining
more than 1 isolate from the same patient at different time
points after recurrence and confirming that they were identical.
We also compared the DNA fingerprints of samples in 20% of
the cases processed in the laboratory on the same day to rule
out laboratory cross-contamination. Furthermore, strains that
were clustered by MIRU were differentiated by spoligotyping
and RFLP, and similarly isolates that were clustered by spoli-
gotyping and RFLP were differentiated by MIRU. Hence, a
reliable estimate of exogenous and endogenous infection could
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Figure 4. Spoligotyping pattern of data of tuberculosis isolates from human immunodeficiency virus (HIV)–infected and HIV-uninfected patients, at
baseline and recurrence.
Table 3. IS6110 Restriction Fragment Length Polymorphism (RFLP) and Spoligo-
typing Clusters Differentiated by Mycobacterial Interspersed Repeat Unit (MIRU)
Patient ID
IS6110
RFLP Spoligotyping MIRU
Cluster 1
V037 1A 477777777413031 2 4 2 4 4 3 3 3 6 1 2 4 4 4 1
V040 1A 477777777413031 2 4 2 4 4 3 6 3 6 1 2 4 4 0 1
J001 1A 477777777413071 2 4 5 4 4 3 3 2 6 1 2 5 4 0 1
V008 1A 477777777413071 2 4 5 4 4 3 4 2 4 1 2 4 4 7 1
V044 1A 477777777413071 5 2 3 4 3 4 2 4 6 1 4 1 3 6 6
J030 1A 477777777413071 5 2 4 4 3 4 2 4 6 1 4 1 3 6 2
J030 1A 477777777413071 5 2 4 4 3 5 2 4 6 1 2 1 3 6 5
J034 1A 477777777413071 5 2 4 4 3 5 2 4 6 1 2 1 3 7 6
J083 1A 477777777413071 7 1 5 4 3 4 2 4 6 1 4 1 3 7 7
Cluster 2
V008 1A 477777777413771 2 4 4 4 4 3 4 3 6 1 2 6 4 6 1
J001 1A 477777777413771 2 4 5 4 4 3 6 0 0 1 2 5 4 0 1
J001 1A 477777777413771 2 4 5 4 4 3 6 2 0 1 2 5 4 0 1
L025 1A 477777777413771 5 2 2 4 3 5 2 4 6 1 4 1 3 6 2
Cluster 3
L048 1A 477777777413031 5 2 4 4 3 4 2 4 6 1 2 1 3 6 6
L150 1A 477777777413031 5 2 4 6 3 4 2 4 6 1 4 1 3 6 6
L174 1A 477777777413031 8 2 4 4 3 4 2 4 6 1 9 1 3 6 6
Cluster 4
L138 1A 477777777413071 5 2 3 4 3 4 2 4 6 1 4 1 3 6 5
L095 1A 477777777413071 5 2 4 4 3 4 2 4 6 1 4 1 3 6 6
L163 1A 477777777413071 5 2 4 4 3 4 2 4 6 1 4 1 3 8 6
L130 1A 477777777413071 5 2 4 4 3 5 2 4 6 1 4 1 3 10
6
L121 1A 477777777413071 5 2 5 4 3 4 3 4 6 1 4 1 3 6 6
L174 1A 477777777413071 8 2 4 4 3 4 2 4 6 1 9 1 3 6 6
NOTE. RFLP, restriction fragment length polymorphism.
be obtained by using multiple genotyping methods to finger-
print tuberculosis clinical isolates.
We have previously reported that ∼40% of M. tuberculosis
strains in South India carry a single copy of IS6110, making it
difficult to use this as the sole method for typing [10]. In this
study also, 45%–47% of patients were infected with a single-
copy strain, regardless of HIV status. MIRU-VNTR typing is a
promising method with high discriminative characteristics that
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Table 4. Clustering of Relapse Isolates of Human Immunodefi-
ciency Virus–Negative Patients with Tuberculosis
IS6110
RFLP Spoligotyping MIRU
All 3
genotyping
Total no. of isolates 23.0 23.0 23.0 23.0
No. of isolates in cluster 13.0 15.0 3.0 0.0
No. of clusters 2.0 5.0 1.0 0.0
Range 2–11 2–5 3.0 0.0
Percentage 47.8 43.5 8.7 0.0
NOTE. MIRU, mycobacterial interspersed repeat unit; RFLP, restriction
fragment length polymorphism.
Table 5. Clustering of Relapse Isolates of Human Immunode-
ficiency Virus–Positive Patients with Tuberculosis
IS6110
RFLP Spoligotyping MIRU
All 3
genotypes
Total no. of isolates 25.0 25.0 25.0 25.0
No. of isolates in cluster 16.0 19.0 6.0 3.0
No. of clusters 3.0 5.0 3.0 1.0
Range 2–11 2–9 2.0 3.0
Percentage 52.0 56.0 12.0 8.0
NOTE. MIRU, mycobacterial interspersed repeat unit; RFLP, restriction
fragment length polymorphism.
can be used to differentiate IS6110 single-copy isolates. Ge-
notypic strategies using 2 or more PCR-based methods have
been proposed for investigations into tuberculosis epidemio-
logical profile and phylogeny [30, 31]. Spoligotyping showed
that the EAI3 and EAI5 clades of M. tuberculosis are most
prevalent in this region, with the Beijing strain being rare. This
is similar to previous reports from South India [32] but dif-
ferent from clades commonly observed (type 26, Delhi type,
type 54) in North India [33].
In many countries, facilities for care and treatment of patients
with HIV/AIDS and tuberculosis overlap, creating opportuni-
ties for nosocomial transmission and cross-infection. This may
be one of the reasons for the high rate of exogenous reinfection
seen in our study, because many of our patients had spent time
in hospital wards where they could have been exposed to in-
fectious patients with tuberculosis. Unfortunately, because of
the large number of in-patients and high turnover in these
hospitals, we were unable to actually prove nosocomial trans-
mission. There is indirect evidence for this because clustering
of recurrence isolates was greater among HIV-infected than
HIV-uninfected patients (Tables 4 and 5). Recurrences among
HIV-uninfected patients with tuberculosis appear to be due
mainly to reactivation of mycobacteria in lesions that have been
incompletely sterilized by the antituberculosis drugs, a phe-
nomenon that is incompletely understood. In this study, half
the patients had received a trial regimen of 4 or 5 months
duration (with ofloxacin), whereas the other half had received
the standard 6-month short-course regimen. Regardless of the
regimen, almost all the recurrences were due to reactivation.
One of the limitations of our study is that not all recurrences
that occurred during this period could be included, usually
because either the baseline or recurrence isolate was unavailable
for genetic analysis or all 3 techniques had not been used. Thus,
a potential bias could have occurred as a result of selectivity
of specimens studied. Furthermore, the number of patients with
recurrences studied is not an indication of the overall efficacy
of the regimens under trial. In fact, it is well known that re-
currence rates are higher among HIV-infected patients with
tuberculosis [34, 35]. In a pilot study of patients with advanced
HIV and tuberculosis treated with a 6-month regimen, we ob-
served a favorable response of 72% at the end of treatment and
during 2 years of follow-up, a mortality rate of 35% and tu-
berculosis recurrence rate of 39% [36]. Some of the patients
in the present report were participants in a randomized clinical
trial comparing 6 and 9 months antituberculosis treatment,
results of which have been submitted for publication separately
[13]. There, we describe the outcome of tuberculosis treatment,
including failures and recurrences and mention of DNA fin-
gerprinting results. Here, we report the details of strain typing
using robust molecular methods among recurrences that oc-
curred in the HIV clinical trial and have used data from con-
currently treated HIV-uninfected patients with tuberculosis for
comparison. Hence, we are not comparing tuberculosis out-
comes between these 2 very different groups but only the nature
of recurrences.
In the ofloxacin trial among HIV-negative patients, recur-
rence rates ranged from 2% to 13% for the different regimens,
whereas the rate for patients treated using the standard short-
course regimen in the tuberculosis control program has been
reported to be in the range of 11%–12% [14, 37]. We believe
the fact that half the HIV-uninfected patients received a non-
standard antituberculosis regimen (with ofloxacin) does not
change the interpretation of the results because of the over-
whelming preponderance of reactivation in this group, regard-
less of regimen received. The strengths of this study are the
concurrent nature of the 2 treatment trials and the identical
setting under which they were conducted (ensuring compar-
ability), as well as the excellent follow-up and documentation
of treatment outcomes. Furthermore, we have taken care to
distinguish true reinfection from other potential causes of strain
differences.
Our results suggest that different strategies would be required
to reduce tuberculosis recurrences in these 2 groups of patients.
For HIV-uninfected patients (still the majority of tuberculosis
cases in India), these may include vaccines to boost cell-me-
diated immune responses, intensification of regimens to ensure
Figure 5A.
Figure 5B.
Figure 5. Combined dendrogram based on the similarities of the isolates, using all 3 genotyping methods: IS6110 restriction fragment length
polymorphism (RFLP), spoligotyping, and mycobacterial interspersed repeat unit (MIRU).
702 • JID 2010:201 (1 March) • Narayanan et al
complete sterilization of lesions, and measures to improve treat-
ment adherence. The American Thoracic Society guidelines rec-
ommend that, for those patients with cavitation on baseline
chest X-ray or positive sputum cultures at 2 months, treatment
should be extended to 9 months [37]. However, the Indian
Tuberculosis Control program recommends 6-month treatment
for all new patients with tuberculosis disease. Recent efforts in
drug development suggest that it may be possible to develop
treatment regimens (eg, using fluoroquinolones) that are more
effective (as well as of shorter duration) than those that are
currently available [38]. A real challenge is to ensure that pa-
tients complete 6 months of regular treatment because recur-
rence rates have been shown to correlate with adherence [37].
For HIV-infected patients, strategies to minimize recurrences
would include longer treatment regimens, post-treatment pro-
phylaxis (with 1 or 2 drugs), or initiation of antiretroviral treat-
ment, thereby improving immune status and reducing suscep-
tibility to new infections [39, 40]. Our study also highlights the
importance of infection control in both the hospital and com-
munity settings, particularly in areas with high HIV prevalence.
In summary, our study has documented the differences in
the nature of recurrences observed among HIV-infected and
HIV-uninfected patients after successful treatment of tuber-
culosis disease in South India. Previous reports have been
mainly from Africa; to the best of our knowledge, our data are
the first from a tuberculosis-endemic country in Asia. These
findings have implications for policy makers, as well as clini-
cians who manage patients with tuberculosis.
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